Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

References

• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015 CA. Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al., eds. SEER Cancer Statistics Review. Bethesda (MD): National Cancer Institute; 1975–2014. https://seer.cancer.gov/csr/1975_2014/. Based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
   Google Scholar
• Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–2509. doi:10.1056/NEJMoa1410490.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19(13):3159–3167. doi:10.1093/emboj/19.13.3159.
   PubMed Web of Science ®Google Scholar
• Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007;21(21):2788–2803.
   PubMed Web of Science ®Google Scholar
• Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, Franklin W, Said S, Varella-Garcia M. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(2):111–119.
   PubMed Web of Science ®Google Scholar
• Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118(5):1173–1180. doi:10.1002/ijc.21454.
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 1996;2(5):909–914.
   PubMed Web of Science ®Google Scholar
• Meng X, Wang J, Sun X, Wang L, Ye M, Feng P, Zhu G, Lu Y, Han C, Zhu S, et al. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail. Radiother Oncol. 2013;109(2):275–280. doi:10.1016/j.radonc.2013.09.008.
   PubMed Web of Science ®Google Scholar
• Ha HT, Griffith KA, Zalupski MM, Schuetze SM, Thomas DG, Lucas DR, Baker LH, Chugh R. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma. Am J Clin Oncol. 2013;36(1):77–82. doi:10.1097/COC.0b013e31823a4970.
   PubMed Web of Science ®Google Scholar
• Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, et al. 2017. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: the NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol. 3(11):1520–1528.
   PubMed Web of Science ®Google Scholar
• Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer. A Phase I Study Cancer Sci. 2018;109(3):785–793.
   Google Scholar
• Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012;13(8):600–605. doi:10.4161/cbt.19849.
   PubMed Web of Science ®Google Scholar
• Zhao K, Hu X, Wu X, Fu X, Fan M, Jiang G. A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Invest New Drugs. 2012;30(4):1585–1590. doi:10.1007/s10637-010-9517-0.
   PubMed Web of Science ®Google Scholar
• de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araujo Lima Franca B, Del Giglio A, Lazaretti NS, Alvares MN, Pedrini JL, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer. NICE Trial Eur J Cancer. 2018;88:21–30. doi:10.1016/j.ejca.2017.10.005.
   PubMed Web of Science ®Google Scholar
• Perez R, Moreno E, Garrido G, Crombet T. EGFR-Targeting as a Biological Therapy. Understanding Nimotuzumab‘S Clinical Effects Cancers (Basel). 2011;3(2):2014–2031. doi:10.3390/cancers3022014.
   Google Scholar
• Berger C, Krengel U, Stang E, Moreno E, Helene I. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J Immunother. 2011;34(7):550–555. doi:10.1097/CJI.0b013e31822a5ca6.
   PubMed Web of Science ®Google Scholar
• Zhou C, Zhu L, Ji J, Ding F, Wang C, Cai Q, Yu Y, Zhu Z, Zhang J. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment. In Vivo Curr Cancer Drug Targets. 2017;17(1):89–97. doi:10.2174/1568009616666161013101657.
   Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303. doi:10.1016/j.ccr.2014.02.025.
   PubMed Web of Science ®Google Scholar
• Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24(1):26–34. doi:10.1016/j.tcb.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernandez LE, Crombet T, Kerbel RS, Perez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373–382. doi:10.4161/cbt.11.4.14097.
   PubMed Web of Science ®Google Scholar
• Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851–5859. doi:10.1158/0008-5472.CAN-08-3660.
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM.. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301–311. doi:10.1016/j.ccr.2005.03.003.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Carter P. Tunable antibodies. Nat Biotechnol. 2005;23(5):556–557. doi:10.1038/nbt0505-556.
   PubMed Web of Science ®Google Scholar
• Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70(2):391–395. doi:10.1016/j.ijrobp.2007.07.2325.
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, et al. 2013. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 14(7):627–637.
   PubMed Web of Science ®Google Scholar
• Cosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, et al. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy ± cetuximab in oesophageal cancer. Br J Cancer. 2017;116(6):709–716. doi:10.1038/bjc.2017.21.
   PubMed Web of Science ®Google Scholar
• Zhao L, He LR, Xi M, Cai MY, Shen JX, Li QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, et al. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. J Transl Med. 2012;10:249.
   PubMed Web of Science ®Google Scholar
• Lu M, Wang X, Shen L, Jia J, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Cancer Sci. 2016;107(4):486–490. doi:10.1111/cas.12894.
   PubMed Web of Science ®Google Scholar
• Saumell Y, Sanchez L, Gonzalez S, Ortiz R, Medina E, Galan Y, Lage A. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real. World Adv Ther. 2017;34(12):2638–2647. doi:10.1007/s12325-017-0631-7.
   PubMed Web of Science ®Google Scholar
• Wang CY, Deng JY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, et al. 2015. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. Oncotarget. 6(21):18674–18682.
   PubMedGoogle Scholar
• ClinicalTrials.gov. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma. https://clinicaltrials.gov/ct2/show/NCT02409186; 2018 [accessed 2018 Jun 12].
   Google Scholar